HeartBeam to Showcase FDA-Cleared Cardiac Technology at JP Morgan Healthcare Conference

HeartBeam announced its participation in the JP Morgan 2026 Annual Healthcare Conference scheduled for January 12-15, 2026, in San Francisco. Company executives including Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available for meetings with investors and potential partners during the conference.

The company plans to highlight its recent regulatory milestone: 510(k) clearance from the U.S. Food and Drug Administration for its patented cable-free 12-lead electrocardiogram synthesis software designed for arrhythmia assessment. This clearance represents a crucial step toward the company's planned limited U.S. commercial launch in the first quarter of 2026.

HeartBeam's technology represents a significant advancement in cardiac monitoring by creating the first cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing those signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever patients are located, potentially delivering actionable cardiac intelligence outside traditional medical facilities.

The company's 3D ECG technology initially received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-Lead ECG synthesis software in December 2025. The system is intended for adult patients in either clinical or home settings and is designed to record, store, and transfer 3-lead ECG data acquired from five electrodes.

According to the company's documentation, the synthesized 12-lead ECG output is intended for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The technology is not intended to replace standard 12-lead ECGs or assess more serious cardiac conditions.

The implications of this technology extend beyond the conference discussions. By enabling portable, cable-free cardiac monitoring, HeartBeam's system could potentially transform how cardiac conditions are detected and monitored, allowing physicians to identify cardiac health trends and acute conditions while patients remain outside medical facilities. This approach could redefine cardiac health management by making sophisticated monitoring more accessible and convenient.

HeartBeam holds over 20 issued patents related to its technology enablement, providing intellectual property protection as it moves toward commercialization. The company's participation in the JP Morgan Healthcare Conference represents an opportunity to engage with potential commercialization and co-development partners who could help accelerate the technology's market adoption.

For additional information about the company's technology and regulatory clearances, visit HeartBeam.com. The company's regulatory documentation emphasizes that the synthesized 12-lead ECG output is not intended for assessment of more serious conditions including ventricular arrhythmias, myocardial infarction, ischemia, or other disorders requiring standard diagnostic equipment.

As the healthcare industry continues to shift toward remote monitoring and telehealth solutions, technologies like HeartBeam's cable-free ECG system could play an increasingly important role in managing cardiac health outside traditional clinical settings. The company's presence at the JP Morgan Healthcare Conference signals its readiness to engage with industry leaders and investors about this potentially transformative approach to cardiac care.